| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to compounds of formula n n n n wherein A 1 represents N or C (A 2 ); A 2 represents H, F, Cl or CN; B 1 represents H, OR 1 , SO 2 R 1 , NHR 1 , NHC(O)R 1 , F or Cl; D 1 and E 1 represents H or Cl; Y 1 represents H, CN, NO 2 , F, Cl, Br, CF 3 , R 17 , OR 17 , SO 2 R 17 or C(O)NH 2 ; or Y 1 and B 1 together with atoms to which they are attached, represent 5- or 6-merous heteroarene having 2-3 nitrogen atoms, wherein heteroarene rings are unsubstituted or substituted by (O); G 1 represents H; Z 1 represents uncondensed phenylene substituted by OR 41 ; R 41 represents 6-merous heteroaryl having 1 N atom, wherein heteroaryl is condensed with R 43A , R 43A represents 5-merous heteroarene having 1 N atom; Z 2 represents monocyclic 6-merous heterocycloalkylene having 1-2 N atoms and 0 double bonds; Z 1A and Z 2A are both absent; L 1 represents -CH 2 -; Z 3 represents R 38 or R 40 ; R 38 represents uncondensed phenyl; R 40 represents cycloalkyl, wherein cycloalkyl represents a monocyclic ring system having 3 to10 C atoms and 0 double bonds, cycloalkenyl, wherein cycloalkenyl represents monocyclic 6-merous ring having 1 heteroatom specified in a group consisting of O and N, and 1 double bond, wherein cycloalkenyl is uncondensed or condensed with R 40A ; R 40A represents cycloalkane, wherein cycloalkane represents a monocyclic ring having 3-10 C atoms and 0 double bonds, or heterocycloalkane, wherein heterocycloalkane represents monocyclic 6-merous ring having 1 N atom and 0 double bonds (the rest substitutes are those as specified in cl. 1 of the patent claim). The invention also refers to compounds of formula n n n n and a pharmaceutical composition containing an effective amount of the compound of formula (I) or (II) or its pharmaceutically acceptable salt. n EFFECT: compounds of formula (I) or (II) inhibiting the activity of anti-apoptotic Bcl-2 proteins. n 6 cl, 5 tbl, 378 ex |